Inovio Biomedical to Present at Global Vaccine Conferences

http://www.businesswire.com/news/home/20091112005309/en

SAN DIEGO--(Business Wire)--
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design,
development and delivery, announced today that the company will highlight its
technology at two worldwide vaccine conferences next week. Dr. David Weiner,
Chair of Inovio`s Scientific Advisory Board, and Niranjan Sardesai, Senior Vice
President, SVP, Research and Development will speak on Inovio`s DNA vaccine
development.

VACCINES EUROPE
Brussels, Belgium
Wednesday, November 18th, 12:20PM
Conference 1: Vaccine Discovery and Development
"Engineering DNA vaccine potency in vivo results in improved Immunity: Improving Vaccine Immunogenicity and Efficacy"

Dr. David Weiner, Chair, Inovio Scientific Advisory Board
Department of Pathology and Laboratory Medicine
Chair, Gene Therapy and Vaccine Program, CAMB
University of Pennsylvania

INFLUENZA CONGRESS USA 2009
Washington, DC
Thursday, November 19th, 2:30PM
Research & Development Program
"Development of Universal SynCon DNA Vaccines for Pandemic and Seasonal Influenza"

Dr. Niranjan Sardesai, Senior Vice President, Research & Development
Inovio Biomedical Corporation

About Inovio Biomedical Corporation

Inovio Biomedical is focused on the design, development, and delivery of a new
generation of vaccines, called DNA vaccines, to prevent and treat cancers and
infectious diseases. The company`s SynCon technology enables the design of
"universal" vaccines capable of protecting against multiple - including newly
emergent, unknown - strains of pathogens such as influenza. Inovio`s proprietary
electroporation-based DNA vaccine delivery technology has been shown by initial
human data to safely and significantly increase gene expression and immune
responses. Inovio`s clinical programs include HPV/cervical cancer (therapeutic)
and HIV vaccines. An IND has been filed for an avian influenza vaccine. Inovio
is developing its universal and avian influenza vaccines in collaboration with
scientists from the University of Pennsylvania, the National Microbiology
Laboratory of the Public Health Agency of Canada, and the NIH`s Vaccine Research
Center. Other partners and collaborators include Merck, Tripep, University of
Southampton, National Cancer Institute, and HIV Vaccines Trial Network. More
information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to,
among other things, our plans to develop electroporation-based drug and gene
delivery technologies and DNA vaccines. Actual events or results may differ from
the expectations set forth herein as a result of a number of factors, including
uncertainties inherent in clinical trials and product development programs,
including but not limited to the fact that pre-clinical and clinical results
referenced in this release may not be indicative of results achievable in other
trials or for other indications, that results from one study may not necessarily
be reflected or supported by the results of other similar studies, that results
from an animal study may not be indicative of results achievable in human
studies, thatclinical testing is expensive and can take many years to complete,
that the outcome of any clinical trial is uncertain and failure can occur at any
time during the clinical trial process, and that our electroporation technology
and DNA vaccines may fail to show the desired safety and efficacy traits in
clinical trials; the availability of funding; the ability to manufacture vaccine
candidates; the availability or potential availability of alternative therapies
or treatments for the conditions targeted by us or our collaborators, including
alternatives that may be more efficacious or cost-effective than any therapy or
treatment that we and our collaborators hope to develop; whether our proprietary
rights are enforceable or defensible or infringe or allegedly infringe on rights
of others or can withstand claims of invalidity; the impact of government
healthcare proposals and other factors set forth in our Annual Report on Form
10-K for the year ended December 31, 2008, our Form 10-Q for the quarterly
period ended June 30, 2009, and other regulatory filings from time to time.
There can be no assurance that any product in Inovio`s pipeline will be
successfully developed or manufactured, that final results of clinical studies
will be supportive of regulatory approvals required to market licensed products,
or that any of the forward-looking information provided herein will be proven
accurate.

Investors:
Inovio Biomedical
Bernie Hertel, 858-410-3101
or
Media:
Richardson & Associates
Jeff Richardson, 805-491-8313

Copyright Business Wire 2009